We are proud to share that our CEO, Alexander Seyf, was featured in Technology Networks Biopharma’s latest analysis on the shifting landscape of US pharmaceutical tariffs and their impact on European manufacturers.

As the industry faces unprecedented uncertainty regarding trade policies and reciprocal tariffs, Alexander offers a critical perspective on how these shifts affect the advanced therapy sector—particularly cell and gene therapy (CGT).

Key takeaways include:

👉 Tariff-driven cost increases for European manufacturers don’t just hit the bottom line; they risk diverting vital resources away from R&D and toward risk mitigation, potentially slowing the pace of life-saving breakthroughs.

👉 For complex therapies reliant on specialized international sourcing, tariffs and trade barriers can lead to significant disruptions and drug availability delays.

👉We are seeing a strategic move from “just-in-time” supply chains to more robust “just-in-case” models. This includes building inventory buffers and securing alternative regional sources to ensure operational resilience.

👉 To tackle these hurdles, Alexander highlights the rise of strategic alliances, even among competitors, to share infrastructure and solve pre-competitive manufacturing challenges.

“European pharmaceutical manufacturers are not sitting idly by… They are proactively adapting and prioritizing supply chain resilience and diversification.” – Alexander Seyf

Read the full article here.